Lynch syndrome presenting as endometrial cancer

Clinical Chemistry

Volumn 60, Issue 1, 2014, Pages 111-121

  Tafe, Laura J ^a   Riggs, Eleanor R ^a   Tsongalis, Gregory J ^a,b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER SCREENING; COLORECTAL CANCER; DNA SEQUENCE; ENDOMETRIUM CANCER; FAMILIAL CANCER; GENE MUTATION; GENE SEQUENCE; GENETIC COUNSELING; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; METHYLATION; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; REVIEW;

EID: 84891753996     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2013.206888     Document Type: Review

References (68)

1. American Cancer Society. Cancer facts & figures 2013. http://www.cancer.org/acs/groups/content/ @epidemiologysurveilance/documents/ document/ acspc-036845.pdf (Accessed October 2013). 60 p.
2. National Cancer Institute. Genetics of colorectal cancer (PDQ-). http://www.cancer.gov/cancertopics/ pdq/genetics/colorectal (Accessed June 2013).
3. Patel SG, Ahnen DJ. Familial colon cancer syndromes: an update of a rapidly evolving field. Curr Gastroenterol Rep 2012;14: 428-38.
4. Vasen HF, Blanco I, Aktan-Collan K, Gopie JP, Alonso A, Aretz S, et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut 2013;62: 812-23.
5. Hampel H, Frankel W, Panescu J, Lockman J, Sotamaa K, Fix D, et al. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial carcinoma patients. Cancer Res 2006;66: 7810-7. (Pubitemid 44289242)
6. Hampel H, Panescu J, Lockman J, Sotamaa K, Fix D, Comeras I, et al. Comment on: Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res 2007;67:9603. (Pubitemid 47535953)
7. Warthin AS. Heredity with reference to carcinoma as shown by the study of the cases examined in the pathological laboratory of the University of Michigan, 1895-1913. Arch Intern Med 1913;35: 348-59.
8. Lynch HT, Shaw MW, Magnuson CW, Larsen AL, Krush AJ. Hereditary factors in cancer: study of two large midwestern kindreds. Arch Intern Med 1966;117: 206-12.
9. Barrow E, Hill J, Evans DG. Cancer risk in Lynch syndrome. Familial Cancer 2013;12: 229-40.
10. Wang Y, Wang Y, Li J, Cragun J, Hatch K, Chambers SK, Zheng W. Lynch syndrome related endometrial cancer: clinical significance beyond the endometrium. J Hematol Oncol 2013;6:22.
11. Kunkel TA, Erie DA. DNA mismatch repair. Annu Rev Biochem 2005;74: 681-710. (Pubitemid 40995521)
12. Greenson JK, Huang SC, Herron C, Moreno V, Bonner JD, Tomsho, et al. Pathologic predictors of microsatellite instability in colorectal cancer. Am J Surg Pathol 2009;33: 126-33.
13. Funkhouser WK Jr, Lubin IM, Monzon FA, Zehnbauer BA, Evans JP, Ogino S, et al. Relevance, pathogenesis and testing algorithm for mismatch repair-defective colorectal carcinomas: a report of the Association for Molecular Pathology. J Mol Diagn 2012;14: 91-103.
14. Moreira L, Balaguer F, Lindor N, de la Chapelle A, Hampel H, Aaltonen LA, et al. Identification of Lynch syndrome among patients with colorectal cancer. JAMA 2012;208: 1555-65.
15. Weissman SM, Burt R, Church J, Erdman S, Hampel H, Holter S, et al. Identification of individuals at risk for Lynch syndrome using targeted evaluations and genetic testing: National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Colorectal Cancer joint practice guideline. J Genet Couns 2012;21: 484-93.
16. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 2009;11: 35-41.
17. Lu KH, Dinh M, Kohlmann W, Watson P, Green J, Syngal S, et al. Gynecologic cancer as a "sentinel cancer" for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol 2005;105: 569-74. (Pubitemid 40271224)
18. Broaddus RR, Lynch HT, Chen LM, Daniels MS, Conrad P, Munsell MF, et al. Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma. Cancer 2006;106: 87-94. (Pubitemid 43032552)
19. Garg K, Leitao MM Jr, Kauff ND, Hansen J, Kosarin K, Shia J, et al. Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities. Am J Surg Pathol 2009;33: 925-33.
20. Jensen KC, Mariappan MR, Putcha GV, Husain A, Chun N, Ford JM, et al. Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age or younger. Am J Surg Pathol 2008;32: 1029-37.
21. Lu FI, Gilks CB, Mulligan AM, Ryan P, Allo G, Sy K, et al. Prevalence of loss of expression of DNA mismatch repair proteins in primary epithelial ovarian tumors. Int J Gynecol Pathol 2012;31: 524-31.
22. Shia J, Black D, Hummer AJ, Boyd J, Soslow RA. Routinely assessed morphological features correlate with microsatellite instability status in endometrial cancer. Hum Pathol 2008;39: 116-25. (Pubitemid 350216167)
23. Tafe LJ, Garg K, Chew I, Tornos C, Soslow RA. Endometrial and ovarian carcinomas with undifferentiated components: clinically aggressive and frequently under-recognized neoplasms. Mod Pathol 2010;6: 781-9.
24. Silva EG, Deavers MT, Bodurka DC, Malpica A. Association of low-grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: a new type of dedifferentiated carcinoma? Int J Gynecol Pathol 2006;25: 52-8. (Pubitemid 44638336)
25. Garg K, Soslow RA. Lynch syndrome (hereditary non-polyposis colorectal cancer) and endometrial carcinoma. J Clin Pathol 2009;62: 679-84.
26. Ryan P, Mulligan AM, Aronson M, Ferguson SE, Bapat B, Semotiuk K, et al. Comparison of clinical schemas and morphologic features in predicting Lynch syndrome in mutation-positive patients with endometrial cancer encountered in the context of familial gastrointestinal cancer registries. Cancer 2012;118: 681-8.
27. Westin SN, Lacour RA, Urbauer DL, Luthra R, Bodurka DC, Lu KH, et al. Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome. J Clin Oncol 2008;26: 5965-71.
28. Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Rüschoff J, et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004;96: 261-8. (Pubitemid 38256271)
29. Beamer LC, Grant ML, Espenschied CR, Blazer KR, Hampel HL, Weitzel JN, MacDonald DJ. Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and followup of abnormal results. J Clin Oncol 2012;30: 1058-63.
30. National Comprehensive Cancer Network. NCCN guidelines: NCCN guidelines for detection, prevention, & risk reduction: colorectal cancer screening. http://www.nccn.org/professionals/physician-gls/ f-guidelines.asp#colorectal- screening (Accessed September 2013).
31. Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. J Mol Diagn 2008;10: 293-300. (Pubitemid 352019113)
32. Modica I, Soslow RA, Black D, Tornos C, Kauff N, Shia J. Utility of immunohistochemistry in predicting microsatellite instability in endometrial carcinoma. Am J Surg Pathol 2007;31: 744-51. (Pubitemid 46684215)
33. Geiersbach KB, Samowitz WS. Microsatellite instability in colorectal cancer. Arch Pathol Lab Med 2011;135: 1269-77.
34. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, et al. A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58: 5248-57. (Pubitemid 28521189)
35. Cicek MS, Lindor NM, Gallinger S, Bapat B, Hopper JL, Jenkins MA, et al. Quality assessment and correlation of microsatellite instability and immunohistochemical markers among population- and clinic-based colorectal tumors: colorectal tumors results from the Colon Cancer Family Registry. J Mol Diagn 2011;13: 271-81.
36. Soreide K. High fidelity of five quasimonomorphic mononucleotide repeats to high frequency microsatellite instability distribution in early stage adenocarcinoma of the colon. Anticancer Res 2011; 31: 967-72.
37. Deschoolmeester V, Baay M, Wuyts W, Van Marck E, Van Damme N, Vermeulen P, et al. Detection of microsatellite instability in colorectal cancer using an alternative multiplex assay of quasi-monomorphic mononucleotide markers. J Mol Diagn 2008;10: 154-9. (Pubitemid 351436269)
38. Hendriks YM, Wagner A, Morreau H, Menko F, Stormorken A, Quehenberger F, et al. Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology 2004;127: 17-25. (Pubitemid 38962270)
39. Parsons MT, Buchanan DD, Thompson B, Young JP, Spurdle AB. Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification. J Med Genet 2012;49: 151-7.
40. Djordjevic B, Barkoh BA, Luthra R, Broaddus RR. Relationship between PTEN, DNA mismatch repair, and tumor histotype in endometrial carcinoma: retained positive expression of PTEN preferentially identifies sporadic non-endometrioid carcinomas. Mod Pathol 2013;26: 1401-12.
41. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 2007;8: 286-98. (Pubitemid 46439286)
42. Pé rez-Carbonell L, Alenda C, Payá A, Castillejo A, Barberá VM, Guillén C, et al. Methylation analysis of MLH1 improves the selection of patients for genetic testing in Lynch syndrome. J Mol Diagn 2010;12: 498-504.
43. Pritchard CC, Smith C, Salipante SJ, Le MK, Thornton AM, Nord AS, et al. ColoSeq provides comprehensive Lynch and polyposis syndrome mutational analysis using massively parallel sequencing. J Mol Diagn 2012;14: 357-66.
44. Abou Tayoun AN, Tunkey CD, Pugh TJ, Ross T, Shah M, Le CC, et al. A comprehensive assay for CFTR mutational analysis using next-generation sequencing. Clin Chem 2013;59: 1481-8.
45. Schneider KA. Counseling about cancer: strategies for genetic counseling, 3rd ed. Hoboken, NJ: Wiley-Blackwell; 2012.
46. Riley BD, Culver JO, Skrzynia C, Senter LA, Peters JA, Costalas JW, et al. Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. J Genet Couns 2012;21: 151-61.
47. National Comprehensive Cancer Network. NCCN Guidelines- [NCCN Clinical Practice Guidelines in Oncology]. http://www.nccn.org/professionals/ physician-gls/f-guidelines.asp#detection (Accessed December 2013).
48. Vasen HF, Wijnen JT, Menko FH, Kleibeuker JH, Taal BG, Griffioen G, et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 1996;110: 1020-7. (Pubitemid 26113739)
49. Stoffel E, Mukherjee B, Raymond VM, Tayob N, Kastrinos F, Sparr J, et al. Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology 2009;137: 1621-7.
50. Aarnio M, Sankila R, Pukkala E, Salovaara R, Aaltonen LA, de la Chapelle A, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999;81: 214-8. (Pubitemid 29144749)
51. Hampel H, Stephens JA, Pukkala E, Sankila R, Aaltonen LA, Mecklin JP, et al. Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology 2005;129: 415-21. (Pubitemid 41096629)
52. Vasen HF, Watson P, Mecklin JP, Jass JR, Green JS, Nomizu T, et al. The epidemiology of endometrial cancer in hereditary nonpolyposis colorectal cancer. Anticancer Res 1994;14: 1675-8. (Pubitemid 24357004)
53. Rijcken FE, Mourits MJ, Kleibeuker JH, Hollema H, van der Zee AG. Gynecologic screening in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 2003;91: 74-80. (Pubitemid 37188596)
54. Dove-Edwin I, Boks D, Goff S, Kenter GG, Carpenter R, Vasen HF, et al. The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma. Cancer 2002;94: 1708-12. (Pubitemid 34241108)
55. Renkonen-Sinisalo L, Bützow R, Leminen A, Lehtovirta P, Mecklin J-P, Järvinen HJ. Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome. Int J Cancer 2007;120: 821-4. (Pubitemid 46175402)
56. Järvinen HJ, Renkonen-Sinisalo L, Aktá n-Collá n K, Peltomäki P, Aaltonen LA, Mecklin JP. Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. J Clin Oncol 2009;27: 4793-7.
57. Weissman SM, Bellcross C, Bittner CC, Freivogel ME, Haidle JL, Kaurah P, et al. Genetic counseling considerations in the evaluation of families for Lynch syndrome - a review. J Genet Couns 2011; 20: 5-19.
58. Lindor NM, Petersen GM, Hadley DW, Kinney AY, Miesfeldt S, Lu KH, et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 2006;296: 1507-17. (Pubitemid 44465515)
59. Vasen HF, Möslein G, Alonso A, Bernstein I, Bertario L, Blanco I, et al. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet 2007;44: 353-62. (Pubitemid 46953715)
60. Koornstra JJ, Mourits MJ, Sijmons RH, Leliveld AM, Hollema H, Kleibeuker JH. Management of extracolonic tumours in patients with Lynch syndrome. Lancet Oncol 2009;10: 400-8.
61. Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology 1999;116: 1453-6. (Pubitemid 29258894)
62. Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005;352: 1851-60.
63. Senter L, Clendenning M, Sotamaa K, Hampel H, Green J, Potter JD, et al. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology 2008;135: 419-28.
64. Moreira L, Balaguer F, Lindor N, de la Chapelle A, Hampel H, Aaltonen LA, et al. Identification of Lynch syndrome among patients with colorectal cancer. JAMA 2012;308: 1555-65.
65. Wernstedt A, Valtorta E, Armelao F, Togni R, Girlando S, Baudis M, et al. Improved multiplex ligation-dependent probe amplification analysis identifies a deleterious PMS2 allele generated by recombination with crossover between PMS2 and PMS2CL. Genes Chromosomes Cancer 2012;51: 819-31.
66. Moline J, Mahdi H, Yang B, Biscotti C, Roma AA, Heald B, et al. Implementation of tumor testing for Lynch syndrome in endometrial cancers at a large academic medical center. Gynecol Oncol 2013;130: 121-6.
67. De Vos M, Hayward BE, Picton S, Sheridan E, Bonthron DT. Novel PMS2 pseudogenes can conceal recessive mutations causing a distinctive childhood cancer syndrome. Am J Hum Genet 2004;74: 954-64. (Pubitemid 38568968)
68. van der Klift HM, Tops CM, Bik EC, Boogaard MW, Borgstein AM, Hansson KB, et al. Quantification of sequence exchange events between PMS2 and PMS2CL provides a basis for improved mutation scanning of Lynch syndrome patients. Hum Mutat 2010;31: 578-87.